132 related articles for article (PubMed ID: 9579425)
1. Field cancerization: why late "recurrent" ovarian cancer is not recurrent.
Buller RE; Skilling JS; Sood AK; Plaxe S; Baergen RN; Lager DJ
Am J Obstet Gynecol; 1998 Apr; 178(4):641-9. PubMed ID: 9579425
[TBL] [Abstract][Full Text] [Related]
2. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations.
Schorge JO; Muto MG; Welch WR; Bandera CA; Rubin SC; Bell DA; Berkowitz RS; Mok SC
J Natl Cancer Inst; 1998 Jun; 90(11):841-5. PubMed ID: 9625172
[TBL] [Abstract][Full Text] [Related]
3. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum.
Bandera CA; Muto MG; Welch WR; Berkowitz RS; Mok SC
Oncogene; 1998 Jul; 16(26):3455-9. PubMed ID: 9692553
[TBL] [Abstract][Full Text] [Related]
4. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
5. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.
Kupryjanczyk J; Thor AD; Beauchamp R; Poremba C; Scully RE; Yandell DW
Mod Pathol; 1996 Mar; 9(3):166-73. PubMed ID: 8685209
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum.
Huang LW; Garrett AP; Muto MG; Colitti CV; Bell DA; Welch WR; Berkowitz RS; Mok SC
Hum Pathol; 2000 Mar; 31(3):367-73. PubMed ID: 10746681
[TBL] [Abstract][Full Text] [Related]
7. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
Jacobs IJ; Kohler MF; Wiseman RW; Marks JR; Whitaker R; Kerns BA; Humphrey P; Berchuck A; Ponder BA; Bast RC
J Natl Cancer Inst; 1992 Dec; 84(23):1793-8. PubMed ID: 1433368
[TBL] [Abstract][Full Text] [Related]
8. Advanced ovarian carcinoma: molecular evidence of unifocal origin.
Li S; Han H; Resnik E; Carcangiu ML; Schwartz PE; Yang-Feng TL
Gynecol Oncol; 1993 Oct; 51(1):21-5. PubMed ID: 8244169
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
10. Genomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction.
Sood AK; Buller RE
Oncogene; 1996 Dec; 13(11):2499-504. PubMed ID: 8957095
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers.
Mitsudomi T; Yatabe Y; Koshikawa T; Hatooka S; Shinoda M; Suyama M; Sugiura T; Ogawa M; Takahashi T
J Thorac Cardiovasc Surg; 1997 Sep; 114(3):354-60. PubMed ID: 9305187
[TBL] [Abstract][Full Text] [Related]
12. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
Buller RE; Sood AK; Lallas T; Buekers T; Skilling JS
J Natl Cancer Inst; 1999 Feb; 91(4):339-46. PubMed ID: 10050867
[TBL] [Abstract][Full Text] [Related]
13. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum.
Muto MG; Welch WR; Mok SC; Bandera CA; Fishbaugh PM; Tsao SW; Lau CC; Goodman HM; Knapp RC; Berkowitz RS
Cancer Res; 1995 Feb; 55(3):490-2. PubMed ID: 7834614
[TBL] [Abstract][Full Text] [Related]
15. Alteration of a p53 gene status affects outcome of patients with recurrent ovarian cancer.
Irie T; Kigawa J; Minagawa Y; Oishi T; Takahashi M; Shimada M; Kamazawa S; Sato S; Terakawa N
Oncology; 2000 Apr; 58(3):237-41. PubMed ID: 10765126
[TBL] [Abstract][Full Text] [Related]
16. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
17. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.
Buller RE; Shahin MS; Holmes RW; Hatterman M; Kirby PA; Sood AK
Am J Obstet Gynecol; 2001 Apr; 184(5):891-902; discussion 902-3. PubMed ID: 11303196
[TBL] [Abstract][Full Text] [Related]
18. Recurrences and second primary tumours in the head and neck region: differentiation by p53 mutation analysis.
Gasparotto D; Maestro R; Barzan L; Vukosavljevic T; Doglioni C; Sulfaro S; Piccinin S; Boiocchi M
Ann Oncol; 1995 Nov; 6(9):933-9. PubMed ID: 8624298
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of peritoneal fluid in ovarian cancer patients.
Parrella P; Zangen R; Sidransky D; Nicol T
Mod Pathol; 2003 Jul; 16(7):636-40. PubMed ID: 12861058
[TBL] [Abstract][Full Text] [Related]
20. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential.
Gu J; Roth LM; Younger C; Michael H; Abdul-Karim FW; Zhang S; Ulbright TM; Eble JN; Cheng L
J Natl Cancer Inst; 2001 Aug; 93(15):1147-52. PubMed ID: 11481386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
